Garching / Munich, Germany — November 10, 2025 — Leads & Copy — ITM Isotope Technologies Munich SE (ITM), a radiopharmaceutical biotech company, announced its participation in upcoming industry investor conferences and events.
ITM’s Chief Executive Officer, Dr. Andrew Cavey, will participate in virtual fireside chats at the William Blair Virtual Radiopharma Conference and in a separate session hosted by Brookline Capital Markets. In addition, Dr. Cavey, along with ITM’s Chief Financial Officer, Dr. Klaus Maleck, will attend the Jefferies London Healthcare Conference 2025.
Dr. Cavey will participate in a virtual fireside chat at the William Blair Virtual Radiopharma Conference on November 13, 2025, at 11:00 am ET / 5:00 pm CET.
Dr. Cavey and Dr. Maleck will be available to meet with conference participants in one-on-one meetings at the Jefferies London Healthcare Conference 2025, held November 17 – 19, 2025.
Dr. Cavey will participate in a virtual fireside chat at the Brookline Capital Markets Fireside Chat on December 16, 2025, at 9:00 am ET / 3:00 pm CET.
ITM, a radiopharmaceutical biotech company, is dedicated to providing radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. The company aims to meet the needs of cancer patients, clinicians, and partners through development, production, and global supply of medical radioisotopes. ITM advances a precision oncology pipeline, including multiple phase 3 studies, combining the company’s radioisotopes with a range of targeting molecules.
By leveraging two decades of radiopharma expertise, ITM strives to provide patients with targeted treatment to improve clinical outcome and quality of life.
ITM Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email: investors@itm-radiopharma.com
ITM Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email: communications@itm-radiopharma.com
Source: ITM Isotope Technologies Munich SE
